Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REMS Barriers: US FDA Takes 'Foundational Step' To Improve Generic Access

Executive Summary

Generic firms might be able to purchase branded drugs for bioequivalence studies from Europe under concepts that FDA is considering. Commissioner Gottlieb says FDA may allow generic firms to seek wavier of shared REMS to avoid protracted negotiations. 

Advertisement

Related Content

Initiator Or Facilitator? Gottlieb Reflects On First Year As Head Of US FDA
Disease-Specific Drug Development Guidances Coming From US FDA In 2018
Disease-Specific Drug Development Guidances Coming From US FDA In 2018
Stakeholders Offer Some Hatch-Waxman Creativity, Highlight Limits Of FDA Action
Stakeholders Offer Some Hatch-Waxman Creativity, Highlight Limits Of FDA Action
Beyond Pay-For-Delay: US FTC Digs Deeper On Barriers To Generic Competition
Beyond Pay-For-Delay: US FTC Digs Deeper On Barriers To Generic Competition
FDA Exploring Whether Public Shaming Can Stop REMS Abuses
Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting

Topics

Advertisement
UsernamePublicRestriction

Register

PS121923

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel